Nationwide Fund Advisors boosted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 3.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 124,351 shares of the company’s stock after acquiring an additional 3,800 shares during the period. Nationwide Fund Advisors owned 0.14% of Neurocrine Biosciences worth $7,620,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in NBIX. Janus Henderson Group PLC bought a new stake in Neurocrine Biosciences in the second quarter valued at approximately $246,888,000. TimesSquare Capital Management LLC boosted its holdings in Neurocrine Biosciences by 299.4% in the second quarter. TimesSquare Capital Management LLC now owns 2,315,373 shares of the company’s stock valued at $106,507,000 after acquiring an additional 1,735,700 shares during the last quarter. HealthCor Management L.P. boosted its holdings in Neurocrine Biosciences by 108.2% in the second quarter. HealthCor Management L.P. now owns 2,550,178 shares of the company’s stock valued at $117,308,000 after acquiring an additional 1,325,178 shares during the last quarter. FMR LLC boosted its holdings in Neurocrine Biosciences by 9.8% in the second quarter. FMR LLC now owns 13,211,023 shares of the company’s stock valued at $607,707,000 after acquiring an additional 1,180,874 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in Neurocrine Biosciences by 53.3% in the second quarter. Goldman Sachs Group Inc. now owns 2,674,217 shares of the company’s stock valued at $123,014,000 after acquiring an additional 930,268 shares during the last quarter.
In other news, insider Christopher Flint Obrien sold 6,925 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $61.04, for a total transaction of $422,702.00. Following the transaction, the insider now directly owns 55,898 shares of the company’s stock, valued at $3,412,013.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Dimitri E. Grigoriadis sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $74.58, for a total value of $2,237,400.00. Following the transaction, the insider now directly owns 77,691 shares in the company, valued at $5,794,194.78. The disclosure for this sale can be found here. Insiders have sold 87,922 shares of company stock worth $6,346,992 over the last ninety days. 4.80% of the stock is owned by insiders.
Several equities analysts have issued reports on the company. Oppenheimer boosted their price target on Neurocrine Biosciences from $70.00 to $85.00 and gave the company an “outperform” rating in a research note on Thursday, November 2nd. Piper Jaffray Companies set a $68.00 price target on Neurocrine Biosciences and gave the company a “buy” rating in a research note on Thursday, August 24th. Citigroup reissued a “buy” rating and issued a $79.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. Needham & Company LLC reissued a “buy” rating and issued a $86.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $84.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, October 5th. One equities research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $78.88.
Neurocrine Biosciences, Inc. (NBIX) opened at $73.75 on Friday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 14.37 and a current ratio of 14.38. Neurocrine Biosciences, Inc. has a 12-month low of $37.35 and a 12-month high of $75.98.
Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Wednesday, November 1st. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.36. The firm had revenue of $60.77 million for the quarter, compared to analyst estimates of $29.38 million. During the same period in the previous year, the company earned ($0.43) earnings per share. equities analysts predict that Neurocrine Biosciences, Inc. will post -1.74 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This story was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.dispatchtribunal.com/2017/12/10/nationwide-fund-advisors-has-7-62-million-position-in-neurocrine-biosciences-inc-nbix.html.
Neurocrine Biosciences Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.